REVIEW ARTICLE

RECORDS OF PHARMACEUTICAL AND BIOMEDICAL SCIENCES

Capitalizing on the Strength of the Ratio Difference Method for Complex Drug Mixture Analysis

Ghada M. Hadad [1], Randa A. Abdelsalam [1], Bassant S. Ahmed [2*] and Abdallah M. Hamdy [2]

[1] Analytical Chemistry Department, Faculty of Pharmacy, Suez Canal University, PO box 41522, Ismailia, Egypt; [2] Analytical Chemistry Department, Faculty of Pharmacy, Egyptian Russian University, Badr City, PO box 11829, Cairo, Egypt.

Received: 03. 11. 2024

Revised: 19. 11. 2024

Accepted: 22. 11. 2024

*Corresponding Author:

E-mail address:

bassant-elsayed@eru.edu.eg

Abstract

One essential tool in pharmaceutical analysis is the Ratio Difference Method (RDM), which provides a sophisticated method for breaking down the complexity of drug mixes. This paper explores the nuances of the RDM and how it might be applied to improve drug combination analysis's accuracy and effectiveness. Through a careful comparison of the ratios of the individual medications in a combination, the RDM helps researchers identify tiny differences and distinguish between different components with more precision. The theoretical foundations of the RDM are explained in this overview, along with its guiding principles and methods. It also examines a wide range of real-world situations, from pharmacokinetic research to quality control evaluations, in which the RDM has proven useful. Through a synthesis of recent advancements and case studies, this article underscores the versatility and utility of the RDM in addressing the evolving challenges of pharmaceutical analysis. Emphasizing its role in enhancing drug formulation strategies, optimizing therapeutic regimens, and elucidating complex drug interactions, this review advocates for the widespread adoption of the RDM as a cornerstone technique in contemporary pharmaceutical research and development.

Keywords: Ratio Difference Method; Pharmaceutical Analysis; Drug Mixtures; Precision; Efficacy.

1. Introduction

Within the field of pharmaceutical sciences, drug combination analysis is an important undertaking that provides valuable information regarding formulation techniques, therapeutic effectiveness, and patient safety. Modern pharmaceutical formulations are becoming more and more complicated, making sophisticated analytical methods essential for deciphering the subtleties of drug interactions. The Ratio Difference Method (RDM) stands out as one of these methods' most potent tools, enabling improved drug mixture analysis and interpretation.(Lotfy et al., 2012)

Based on the concepts of comparative analysis, the RDM offers a methodical way to identify minute differences in the proportions of the individual medications in a mixture. In contrast to

conventional techniques that concentrate exclusively on absolute concentrations or spectral features, the RDM provides a distinctive viewpoint by emphasizing relative variations in drug ratios. Researchers can identify differences with greater accuracy thanks to this differential technique, which also improves the accuracy of drug mixture analysis.(Darwish et al., 2011)

At its core, the RDM leverages mathematical algorithms and statistical frameworks to quantify and compare the ratios of individual drugs present in a mixture. By establishing baseline ratios and calculating deviations from these values, researchers can identify and characterize distinct components within complex mixtures. Furthermore, the RDM allows for the assessment of variability in drug ratios across different batches or formulations, providing valuable insights into formulation consistency and quality control measures.(El-Gindy et al., 2004)

The application of the RDM extends beyond basic compositional analysis, encompassing a wide range of pharmaceutical scenarios and challenges. In the context of pharmacokinetics, the RDM enables researchers to elucidate the absorption, distribution, metabolism, and excretion (ADME) profiles of co-administered drugs, guiding dose optimization and therapeutic regimen design. Moreover, the RDM finds utility in studying drug-drug interactions, offering a comprehensive framework for assessing the synergistic, antagonistic, or additive effects of combined therapies.(Issa et al., 2017)

Recent developments in computational techniques and analytical instrumentation have increased the RDM's potential and made high-throughput screening, multi-dimensional analysis, and predictive modeling possible. Due to these advancements, the RDM is now regarded as a fundamental method in modern pharmaceutical research and development, enabling customized medicine strategies, formulation improvement, and quick drug discovery.(Erk, 2001)
Our goal in writing this review is to give a thorough introduction to the RDM, covering its theoretical underpinnings, methodological nuances, and real-world applications in pharmaceutical analysis. We advocate for the general use of the RDM as a common practice in pharmaceutical research and development, highlighting its versatility and value in tackling the developing issues of drug combination analysis through a synthesis of recent literature and case examples.(Tallarida, 1992)

2. Reported Methods of analysis

2.1. Theoretical Foundations of the Ratio Difference Method (RDM):

Based on the ideas of mathematical modeling and comparative analysis, the Ratio Difference Method (RDM) is a fundamental tool in pharmacological investigation. Essentially, the goal of the RDM is to offer a methodical framework for measuring and analyzing differences in drug ratios in intricate mixes. This section explores the RDM's theoretical foundations in greater detail, illuminating important ideas that serve as the cornerstone of its methodology.(Graf vd Schulenburg et al., 2007)

Baseline ratios are one essential idea at the heart of the RDM. By acting as benchmarks against which variations are gauged, these baseline ratios offer a consistent foundation for comparison between various samples and formulations. Researchers can evaluate the relative abundance of each medication component in a combination and identify deviations from predicted values by setting baseline ratios for each drug component.(Giron et al., 2007)

An additional crucial component of the RDM methodology is the computation of deviations. By means of meticulous mathematical computations, scientists measure the number of variations noted in medication proportions, offering valuable perspectives on the degree of heterogeneity present in a blend. With the use of this quantitative method, researchers can find anomalies, outliers, and possible sources of variability, leading to a more sophisticated knowledge of the fundamental makeup of pharmacological mixes.(Elzanfaly et al., 2012). Testing for statistical significance is essential to verifying the results of the RDM. Researchers can evaluate the importance of observed deviations and discern between meaningless fluctuations and significant trends by utilizing strong statistical approaches. By using a rigorous statistical methodology, RDM studies become more reliable and reproducible, and findings derived from experimental data are supported by strong statistical principles.(Dinç et al., 2002). The core of the RDM is made up of mathematical algorithms, which provide computational tools for processing and analyzing

data. Researchers can improve the accuracy and precision of RDM measurements by accounting for fluctuations in sample concentration and matrix effects through the use of ratio normalization approaches, such as external calibration and internal standardization. Comparably, similarity indices offer quantifiable measurements of similarity between various samples, allowing researchers to evaluate the degree of resemblance and spot patterns within intricate datasets. Examples of these indices are the Pearson correlation coefficient and the Jaccard similarity coefficient .(Ternes, 2001)

All things considered, the theoretical underpinnings of the RDM are based on a multidisciplinary methodology that incorporates ideas from analytical chemistry, statistics, and mathematics. The RDM offers a strong framework for characterizing the composition, quality, and performance of drug mixes by combining these several approaches, opening up new avenues for breakthroughs in pharmaceutical research and development. (Palabiyik et al., 2004)

2.2. Methodological Approaches to Implementing the RDM:

Applying the Ratio Difference Method (RDM) requires careful consideration of data collection, analysis, and experimental design. This section attempts to give a thorough overview of the methodological strategies used in RDM investigations, covering everything from sample preparation methods to computational algorithms.

Techniques for preparing samples are an essential first step in RDM investigations since they have a direct impact on the accuracy and consistency of analytical data. Sample extraction techniques must be carefully chosen by researchers to maximize target analyte recovery and minimize interference from matrix components. Additionally, the preparation solvent and sample matrix selections should be made with the unique properties of the medications being studied in mind, taking into account things like stability, solubility, and possible interactions.(Dinç et al., 2000)

Data acquisition techniques, when combined with sample preparation, are essential to RDM investigations as they determine the sensitivity, accuracy, and precision of analytical measures. High-performance liquid chromatography (HPLC), gas chromatography-mass spectrometry (GC-MS), and nuclear magnetic resonance spectroscopy (NMR) are examples of advanced analytical instruments that provide unmatched resolution and specificity for evaluating complicated mixtures. Through the utilization of cutting-edge equipment and refined analytical procedures, scientists can improve the consistency and resilience of RDM assessments, consequently guaranteeing the dependability of study findings.

The foundation of RDM investigations are analysis procedures, which offer computational tools for handling, analyzing, and displaying analytical data. By using mathematical methods like principal component analysis (PCA), regression analysis, and multivariate statistical analysis, researchers can uncover patterns or trends in complicated datasets that might not be seen by eye inspection alone. Furthermore, the use of machine learning techniques presents significant potential for improving the capabilities of RDM investigations by permitting automated data analysis, predictive modeling, and pattern recognition.(Abdul-Fattah et al., 2007)

For RDM measurements to be accurate and repeatable, it is essential to develop suitable reference standards and calibration curves. Pharmaceutical-grade compounds or recognized reference materials are used to create calibration standards, which are used as benchmarks for calculating drug concentrations and confirming analytical techniques. The reliability of RDM data may be confirmed and potential sources of bias or error can be reduced by researchers by calibrating analytical instruments against established standards and carrying out routine quality control checks.

Moreover, new developments in RDM approaches, such the fusion of high-throughput screening platforms with machine learning algorithms, have the potential to completely transform the pharmaceutical analytical industry. With the use of machine learning algorithms that have been trained on big datasets of RDM measurements, researchers can achieve previously unheard-of levels of accuracy when predicting therapy results, finding new medication combinations, and optimizing formulation techniques. Drug discovery and formulation development can proceed more quickly thanks to high-throughput screening devices that can quickly screen huge libraries of drug mixes

thanks to their robotic automation and sophisticated data analytics capabilities.(Jelić et al., 2009) thanks to their robotic automation and sophisticated data analytics capabilities.(Jelić et al., 2009)

2.3. Practical Applications of the RDM in Pharmaceutical Analysis

Pharmaceutical analysis benefits greatly from the Ratio Difference Method (RDM), which provides insightful information on pharmacokinetic investigations, formulation development, and quality control. This section explores the RDM's real-world uses, explaining its value with case studies and real-world examples that highlight its adaptability and effectiveness in solving a range of analytical problems

2.3.1. Assessment of Drug Uniformity in Solid Dosage Forms:

Researchers can assess the consistency of drug distributions in solid dosage forms, like tablets and capsules, with the use of the RDM. Researchers can detect differences in medication concentration and guarantee uniform drug distribution by analyzing the ratios of active pharmaceutical ingredients (APIs) in various dosage form areas. The consistency of drug distribution in solid dosage forms is crucial for preserving pharmaceutical products' safety and efficacy. One useful technique for evaluating drug homogeneity in tablets, capsules, and other solid dosage forms is the Ratio Difference Method (RDM). Researchers can obtain important insights into the spatial distribution of active pharmaceutical ingredients (APIs) in these formulations by utilizing the concepts of comparative analysis. By comparing the API ratios in various dosage form regions, the RDM provides a methodical way to assess drug homogeneity. Through the use of comparative analysis, researchers are able to discover possible areas of non-uniformity by detecting changes in drug concentration between different sections of the tablet or capsule. Through the quantification of variances in drug ratios, researchers may evaluate the degree of uniformity present in the dosage form and guarantee that patients receive their medication consistently. The capacity of the RDM to offer geographical data regarding drug distribution within the dosage form is one of its primary advantages when evaluating drug uniformity. Conventional approaches to evaluate drug homogeneity frequently depend on bulk analytical methods that yield averaged measurements over the whole dose form. On the other hand, the RDM allows researchers to identify certain areas of interest within the dosage form and assess the localized concentration of the drug. When finding localized differences in drug content that may not be visible by bulk analysis alone, this spatial resolution is especially helpful. Additionally, the RDM can be used with a variety of solid dosage forms, such as multiparticulate formulations, tablets, and capsules. The RDM provides a versatile and adaptive method for evaluating drug homogeneity across different formulations, regardless of whether the drug is present in a single tablet or several drug-loaded beads in a multiparticulate formulation. Because of its adaptability, researchers can customize their analysis to the unique properties of each dosage form, guaranteeing precise and trustworthy results

The RDM can be used to optimize drug delivery systems during formulation development, in addition to assessing medication uniformity in completed dosage forms. Researchers can determine formulation techniques that support more consistent medication release and absorption by evaluating the effects of formulation parameters on drug uniformity, such as excipient composition and manufacturing circumstances. By taking a proactive approach to formulation optimization, the risk of non-uniform drug distribution can be reduced and pharmaceutical product quality can be raised overall.(Huang & Ku, 2010)

2.3.2. Detection of Impurities and Adulterants in Complex Mixtures

In complicated mixtures, the RDM is an effective method for identifying adulterants and contaminants. Researchers can protect the integrity and safety of pharmaceutical goods by differentiating between real pharmaceutical ingredients and contaminants by comparative study of medication ratios. Pharmaceutical analysis plays a crucial role in maintaining the safety and integrity of pharmaceutical goods by identifying adulterants and contaminants in complicated mixtures. Researchers may now accurately and precisely discriminate between contaminants and real medicinal ingredients by using the powerful Ratio Difference Method (RDM) to detect and measure impurities and adulterants, as shown in **Fig. 1.**



Figure 1. (**a**) With 10% urea added to milk, protein peaks can be visibly clearer and concentrated. (**b**) No adulterant was added to milk (Porwal et al., 2024).

Comparative examination of drug ratios is one of the main benefits of using the RDM for adulterant and impurity detection. Researchers can identify minute differences that can point to the presence of contaminants by comparing the ratios of active pharmaceutical ingredients (APIs) in the presence and absence of adulterants or impurities. By using a differential technique, researchers may detect contaminants at minuscule levels that could otherwise go undetected, improving impurity detection sensitivity and specificity.

Additionally, the RDM provides a quantitative framework for determining how contaminated a complex mixture is. Researchers can estimate the proportion of contaminants or adulterants in the sample by assessing the number of deviations in medication ratios. This information is useful for regulatory compliance and quality control. Through the use of quantitative analysis, researchers can establish acceptable contamination thresholds and put necessary safety precautions in place for patients

The RDM's adaptability covers a wide range of contaminants and adulterants that are frequently found in pharmaceutical products. Detecting and quantifying organic impurities, inorganic pollutants, and adulterants like fake medications or unreported components can be done with flexibility and adaptability using the RDM method. Because of its adaptability, researchers can customize their analysis to the unique properties of every kind of adulterant or impurity, resulting in accurate and dependable results for a variety of applications.

The RDM can be used in forensic investigations and regulatory compliance testing in addition to its function in regular quality control assessments. Through the examination of drug ratios in samples sourced from dubious sources or in items thought to include adulterants, researchers can offer forensic proof to bolster legal cases and enforcement initiatives. Moreover, the RDM can support regulatory bodies in ensuring public health and consumer confidence by helping them monitor the safety and legitimacy of pharmaceutical items on the market.

In the future, it is anticipated that the RDM's capacity to identify contaminants and adulterants will be significantly improved by the ongoing development of analytical and computational techniques. The sensitivity, specificity, and effectiveness of impurity detection techniques could be increased with the use of emerging technologies including machine learning algorithms, chromatographic separation techniques, and high-resolution mass spectrometry. Through the utilization of these advancements, scientists can remain ahead of developing risks to pharmaceutical efficacy and security, guaranteeing that patients obtain the best possible medicines(Prajapati & Agrawal, 2014)

2.3.3. Optimization of Drug Delivery Systems for Enhanced Bioavailability

Researchers can improve drug delivery systems to increase bioavailability and therapeutic efficacy by using the RDM. Through the analysis of medication component ratios in various formulations or delivery systems, researchers can determine which formulations facilitate the best possible drug release and absorption, leading to improved patient outcomes. In order to increase a medicine's therapeutic efficacy and bioavailability, pharmaceutical research must prioritize the optimization of drug delivery systems. Researchers can use a methodical approach to improve patient outcomes and optimize drug delivery systems by utilizing the Ratio Difference Method (RDM). Through the analysis of medication component ratios in various formulations or delivery vehicles, researchers can determine which formulations maximize therapeutic efficaciousness and minimize side effects by promoting optimal drug release and absorption.

The RDM gives quantitative insights into the makeup and behavior of formulations, making it a potent paradigm for assessing the efficacy of drug delivery systems. Researchers can evaluate the effects of formulation characteristics, such as excipient composition, drug loading, and particle size, on drug release kinetics and absorption patterns by comparing the ratios of active pharmaceutical ingredients (APIs) in various formulations. Through comparative analysis, researchers can find formulations that optimize patient outcomes by striking the ideal balance between quick start of action and continuous drug release.

The capacity of the RDM to offer mechanistic insights into the underlying mechanisms controlling drug release and absorption is one of its main advantages in terms of optimizing drug delivery systems. Researchers can clarify how formulation parameters affect medication solubility, permeability, and stability by measuring the extent of differences in drug ratios between various formulations. Researchers may create formulations with customized release profiles and enhanced bioavailability thanks to this mechanistic insight, which improves the therapeutic efficacy of medications for a variety of therapeutic purposes.

Additionally, the RDM gives researchers the option to screen formulation variables systematically in order to find the best formulations with the highest levels of bioavailability. Through an assessment of excipient type, concentration, and manufacturing process impacts on drug release and absorption, scientists can determine formulation techniques that optimize medication bioavailability while reducing batch-to-batch variability. This proactive approach to formulation optimization lowers the likelihood of formulation failure and expensive late-stage adjustments while also speeding up the medication development process.

Apart from its function in formulation optimization, the RDM can be employed to evaluate the bioequivalence of generic pharmaceutical products in relation to their reference equivalents. Researchers can assess if a generic medicine has similar pharmacokinetic characteristics and therapeutic efficacy by comparing the ratios of APIs in the generic and reference formulations. By using this comparison study, regulatory bodies can ensure patient safety and therapeutic equivalency while deciding whether to approve and commercialize generic medicinal goods

Going forward, it is anticipated that the RDM's capacity for drug delivery system optimization will be further enhanced by the ongoing development of analytical and computational methodologies. Predictive analytics, artificial intelligence, and computational modeling are examples of emerging technologies that show promise for speeding up the formulation development process and improving drug delivery systems with previously unheard-of accuracy and efficiency. Researchers can seize fresh chances to enhance patient outcomes and progress the field of pharmaceutical research and development by using these technologies.(Patel et al., 2019)

2.3.4. Elucidation of Drug-Drug Interactions

Understanding the mechanisms underlying drug-drug interactions and the possible antagonistic or synergistic effects of co-administered medications is made possible by the RDM. Researchers can evaluate how drug interactions affect pharmacokinetic characteristics and therapeutic outcomes by examining changes in drug ratios

when other drugs are present.(Vajna et al., 2011)

2.3.5. Guidance for Selection of Combination Therapies

Researchers can direct the choice of combination medicines for the best possible therapeutic results by utilizing the RDM. Through comparative analysis, researchers can assess the efficacy and compatibility of various pharmacological combinations to find synergistic combinations that maximize therapeutic advantages while reducing side effects.(Szepesi et al., 1991)

To summarise, the RDM has numerous and significant practical applications in pharmaceutical analysis, spanning from guaranteeing product quality and safety to maximising treatment plans. The RDM is still an important instrument for furthering pharmaceutical research and development because of its adaptability and effectiveness.

In clinical practice, choosing combination therapy is a difficult task that calls for rigorous evaluation of drug efficacy, safety, and compatibility. Researchers can direct the choice of combination medicines to maximize therapeutic outcomes for patients by utilizing the Ratio Difference Method (RDM). Through comparative analysis, researchers can assess the efficacy and compatibility of various pharmacological combinations to find synergistic combinations that maximize therapeutic advantages while reducing side effects.(Liu et al., 2021)

In the treatment of many diseases, including cancer, infectious infections, and chronic ailments like diabetes and hypertension, combination therapy has become essential. Combination therapy is justified by the complimentary modes of action of many medications, which can target several biological targets or pathways to produce better therapeutic results than monotherapy. However, choosing the best combination therapy necessitates carefully taking into account a number of variables, including pharmacokinetic characteristics, patient-specific factors including comorbidities and genetic predispositions, and drug-drug interactions.(Khan et al., 2013)

A methodical way to assess the efficacy and compatibility of various pharmacological combinations is the Ratio Difference Method (RDM). Researchers can determine which drug combinations provide the most therapeutic effect by analyzing the ratios of active pharmaceutical ingredients (APIs) in various combinations. This allows researchers to evaluate the degree of synergy or antagonistic interactions across treatments. Researchers can enhance efficacy while lowering the risk of side effects by optimizing drug dosages, dosing schedules, and treatment regimens with the help of this comparative analysis.(Runnqvist et al., 2010)

The RDM's capacity to offer quantitative insights into the interactions of medications is one of its main advantages in helping to choose combination therapy. Researchers can determine the best drug combinations to accomplish the intended therapeutic effect and also clarify the underlying processes of synergy or antagonist by assessing the extent of differences in drug ratios between different combinations. Researchers can create combination medicines with customized pharmacodynamic and pharmacokinetic features according to this mechanistic insight, which improves patient outcomes.(Singh et al., 2019)

Additionally, the RDM makes it possible for scientists to perform a methodical screening of medication combinations in order to find viable candidates for additional clinical assessment. Researchers can find interesting candidates with synergistic effects or increased efficacy over individual medications by testing a variety of pharmacological combinations in vitro or in vivo models. By using this screening method, the time and expense involved in creating novel combination medicines are decreased, and the drug discovery process is expedited.(Hong et al., 2015)

The RDM can be used to optimize current combination regimens in addition to its function in discovering new combination medicines. Through the examination of medication ratios in clinical trials or patient samples, scientists can evaluate the effectiveness and safety of existing combination treatments and pinpoint areas in need of improvement. Researchers can enhance patient outcomes and reduce the chance of treatment-related side effects by fine-tuning treatment regimens, adjusting medication dosages, or investigating alternate combinations thanks to this retrospective review.(Loos et al., 2016)

In the future, it is anticipated that the development of analytical and computational methodologies will significantly improve the RDM's capacity to direct the choice of combination medicines. The fields of systems pharmacology, network analysis, and high-throughput screening are examples of emerging technologies that have the potential to predict the effectiveness of new drug combinations in intricate biological systems. Through the application of these advances, researchers can open up new avenues for precision therapy and personalized medicine, customizing combination medicines for specific patients according to their genetic composition, disease features, and treatment preferences.(Siddiqui et al., 2017)

To sum up, the Ratio Difference Method (RDM) is an effective approach in pharmaceutical research and development that helps with combination therapy selection. The RDM helps researchers find the best drug combinations to enhance therapeutic efficacy while reducing side effects by offering quantitative insights into drug interactions and therapeutic synergy. In the era of precision medicine, the RDM's adaptability and effectiveness propel innovation in combination therapy, propelling pharmaceutical research forward and enhancing patient results.

The FLU ratio spectrum showed the same amplitudes (constant) at the two selected wavelengths (274.5 and 252.3 nm), while the SCG ratio spectrum showed a significant difference in these two amplitude values at these two selected wavelengths with concentration. This was the only requirement for determining the SCG concentration using this method. two additional wavelengths—252 and 305 nm—were chosen in a similar manner for the FLU estimation., as shown in **Fig.2**..(Sheikh et al., 2009)



Figure 2. Ratio spectra of SCG (5 µg/mL), FLU (10 µg/mL) and mixture of 5 µg/mL of SCG and 10 µg/mL of FLU (a) Using 8 µg/mL of FLU as a divisor; (b) Using 10 µg/mL of SCG as a divisor (Lotfy et al., 2012).

To guarantee a low noise to signal ratio at these wavelengths, the linearity of the amplitude values at each selected wavelength against the appropriate concentration should be examined. The noise will be entirely eliminated by using the ratio difference method, which measures the difference between the two amplitude values by subtracting the two values at the two chosen wavelengths

The FLU solution's (8µg/mL) spectrum was divided by the SCG solution's (10µg/mL) spectrum, and the FLU solution's (2–16µg/mL) spectrum by the SCG solution's (10µg/mL) spectrum. The regression equation, which shows the linear relationship between the variations in these ratio spectra amplitudes at the two chosen wavelengths and the corresponding concentration of medication SCG, was used to determine the concentration of SCG. In a similar vein, the same process might be used to determine FLU. The preservative benzoalkonium chloride, which is present in Fluca® eye drops, did not exhibit any absorption during any of the spectral measurements that were conducted. Its contribution to the mixture's absorption above 220 nm was deemed insignificant at concentrations up to 100 µg/mL. As a result, the ternary mixture in the range of 220 - 400 nm functions as a binary mixture of FLU and SCG, as in **Table. 1** listed the relevant concentration ranges, calibration equations, and other statistical parameters for the suggested procedures.

Table 1. Assay parameters and method validation obtained by applying RDM.

Parameters	**SCG**	**FLU**
wavelength (in nm)	274-252	252-305
Calibration range (ug/ml)	2-35	2-16
LOD	0.194	0.125
LOQ	0.589	0.383
slope	0.0707	0.0937
intercept	0.0455	0.0054
Mean %[a]	100.02	100.03
RSD	0.37	0.58
Accuracy recovery RSD%	100.44/0.39	99.97/0.20
repeatability	100.09	100.06
reproducability	100.36	100.16
Robustness	100.21	100.43
correlation coefficient	0.9999	0.9999

[a] average of three experiments

2.3.6. Advancements and Future Directions in Ratio Difference Method Research

Recent years have seen significant progress in the study of the Ratio Difference Method (RDM), driven by developments in data analytics, computer modeling, and analytical equipment. This section explores current advancements and new directions in RDM research, including a wide range of approaches and uses with the goal of enhancing the RDM's potential and usefulness in pharmaceutical analysis and other fields.(Deschamps et al., 2023)

The incorporation of spectroscopic methods, including infrared (IR), Raman, and near-infrared (NIR) spectroscopy, is a noteworthy development in RDM research. With the help of these spectroscopic techniques, pharmaceutical samples can be quickly and non-destructively analyzed, yielding important details about the molecular makeup and composition of drug mixes. Researchers can improve the sensitivity and specificity of drug combination analysis by combining spectroscopic techniques with the RDM. This allows for quick screening of large sample sets and makes it easier to monitor drug formulations in real time during production operations. Moreover, spectroscopic methods

provide continuous process control and quality assurance in pharmaceutical manufacturing facilities by enabling in-line or at-line monitoring of drug mixes.

The incorporation of mass spectrometry (MS) techniques for the thorough characterisation of drug mixes is another area of advancement in RDM research. Pharmaceutical analysis benefits greatly from the high sensitivity and specificity that mass spectrometry provides in identifying and quantifying individual drug components within complex mixtures. Researchers can identify trace-level contaminants, metabolites, and degradation products in drug combination studies by combining MS techniques with the RDM to improve resolution and accuracy. Furthermore, label-free drug component measurement may be possible with mass spectrometry-based methods, doing away with the requirement for expensive and time-consuming sample preparation procedures

Furthermore, by offering reliable statistical techniques for data analysis and interpretation, chemometric approaches significantly contribute to the advancement of the RDM's capabilities. Chemometric methods allow researchers to find hidden patterns, identify outliers or abnormal findings, and extract relevant information from complicated datasets. Examples of these methods include multivariate analysis, principal component analysis (PCA), and partial least squares regression (PLS). Researchers can improve the repeatability and dependability of drug combination analysis, as well as the precision of quantitative measurements and the resilience of statistical models, by combining chemometric techniques with the RDM. Furthermore, data fusion is made possible by chemometric methodologies, which enable researchers to combine data from various analytical methods and sources to provide a more thorough understanding of drug mixes and their characteristics.

Apart from the progress made in analytical techniques, the characterisation of intricate biological matrices such biological fluids and tissue samples is a growing area of interest for RDM research. These biological matrices' diverse composition, variability, and matrix effects provide special difficulties for drug mixture analysis. Nevertheless, combining RDM-based methods with cutting-edge analytical methods like imaging mass spectrometry (IMS) and liquid chromatography-mass spectrometry (LC-MS) shows promise for resolving these issues and providing fresh perspectives on drug distribution, metabolism, and pharmacokinetics in biological systems. Researchers can better understand drug action mechanisms, find indicators of disease development, and optimize therapeutic regimens for personalized medicine methods by studying the spatial distribution of medicines and metabolites inside tissues and organs.(Watson, 2012)

Additionally, opportunities and problems in implementing research findings into clinical practice are being addressed by RDM research. Although the RDM has great promise to enhance drug development and pharmaceutical analytical procedures, a number of challenges need to be addressed before its full effects may be felt in clinical settings. The hurdles encompass standardizing analytical techniques, validating tests based on RDM, and integrating RDM data with patient profiles and clinical results. Ensuring the robustness, repeatability, and reliability of RDM-based analyses in clinical practice requires interdisciplinary collaboration between researchers, physicians, regulatory authorities, and industry partners

Future developments in analytical techniques, computational tools, and applications in pharmaceutical analysis and tailored treatment are all promising for RDM research. New technologies that can be used to improve RDM-based analysis's sensitivity, specificity, and efficiency include microfluidic devices, high-resolution imaging methods, and artificial intelligence (AI) algorithms. Through the utilization of these advancements, scientists can surmount present constraints in medication combination analysis and advance the pharmaceutical sciences discipline towards novel avenues of exploration and creativity. The Ratio Difference Method ultimately holds the potential to transform pharmaceutical analysis, expedite drug development procedures, and enhance patient outcomes in the era of precision medicine with continuous advancements.(Lasztity et al., 2002)

3. Conclusion

Finally, the Ratio Difference Method (RDM) proves to be a flexible and effective tool in the field of pharmaceutical analysis, offering unmatched

understanding of the complex makeup, nature, and functionality of medication combinations. Through the integration of theoretical underpinnings, methodological strategies, actual applications, and future objectives, this review highlights the imperative function of the RDM in advancing pharmaceutical sciences. The RDM is important because it is more than just an analytical tool; it is a spark for creativity and learning. By applying and refining their methods with great care, researchers can overcome the many analytical problems that come with pharmaceutical compositions. Additionally, the RDM provides direction for improving drug formulation techniques, which promotes the creation of safer, more effective pharmaceuticals.

Moreover, the emergence of precision medicine signifies a turning point in healthcare, wherein personalized medicines are administered to patients according to their genetic composition, way of life, and surroundings. According to this paradigm, the RDM plays a critical role in interpreting the complex interactions between medications and biological systems, making it possible to create individualized treatment plans with previously unheard-of accuracy and effectiveness. Looking ahead, the continuous development and improvement of the RDM is closely linked to the future of pharmaceutical sciences. The RDM has the potential to open up new avenues for pharmaceutical research and development as analytical techniques and technology progress. By utilizing the RDM's capabilities, scientists can advance their understanding and solve the puzzles surrounding drug interactions, formulation dynamics, and therapeutic responses.

Essentially, the Ratio Difference Method (RDM) directs researchers toward a more profound comprehension of drug combinations and their consequences for patient care, serving as a beacon of innovation and advancement in pharmaceutical analysis. Let's embrace the RDM's transformational potential as we set out on this research journey and work toward a day where every patient receives the appropriate medication at the appropriate time in an appropriate dosage.

Conflict of Interest

The Authors declare no conflict of interest.

4. References

Abdul-Fattah, A. M., Kalonia, D. S., & Pikal, M. J. , 2007. The challenge of drying method selection for protein pharmaceuticals: product quality implications. Journal of Pharmaceutical Sciences, 96, 1886–1916.

Darwish, H. W., Hassan, S. A., Salem, M. Y., & El-Zeiny, B. A. , 2011. Three different spectrophotometric methods manipulating ratio spectra for determination of binary mixture of Amlodipine and Atorvastatin. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 83, 140–148.

Deschamps, E., Calabrese, V., Schmitz, I., Hubert-Roux, M., Castagnos, D., & Afonso, C. , 2023. Advances in ultra-high-resolution mass spectrometry for pharmaceutical analysis. Molecules, 28, 2061.

Dinç, E., Kökdil, G., & Onur, F. , 2000. A comparison of matrix resolution method, ratio spectra derivative spectrophotometry and HPLC method for the determination of thiamine HCl and pyridoxine HCl in pharmaceutical preparation. Journal of Pharmaceutical and Biomedical Analysis, 22, 915–923.

Dinç, E., Yücesoy, C., & Onur, F. , 2002. Simultaneous spectrophotometric determination of mefenamic acid and paracetamol in a pharmaceutical preparation using ratio spectra derivative spectrophotometry and chemometric methods. Journal of Pharmaceutical and Biomedical Analysis, 28, 1091–1100.

El-Gindy, A., Emara, S., & Hadad, G. M. , 2004. Determination of certain drugs in binary mixtures formulations by second derivative ratio spectrophotometry and LC. Il Farmaco, 59, 703–712.

Elzanfaly, E. S., Saad, A. S., & Abd-Elaleem, A.-E. B. , 2012. Simultaneous determination of retinoic acid and hydroquinone in skin ointment using spectrophotometric technique (ratio difference method). Saudi Pharmaceutical Journal, 20, 249–253.

Erk, N. , 2001. Analysis of binary mixtures of losartan potassium and hydrochlorothiazide by

using high performance liquid chromatography, ratio derivative spectrophotometric and compensation technique. Journal of Pharmaceutical and Biomedical Analysis, 24, 603–611.

Giron, D., Monnier, S., Mutz, M., Piechon, P., Buser, T., Stowasser, F., Schulze, K., & Bellus, M. , 2007. Comparison of quantitative methods for analysis of polyphasic pharmaceuticals. Journal of Thermal Analysis and Calorimetry, 89, 729–743.

Graf vd Schulenburg, J.-M., Vauth, C., Mittendorf, T., & Greiner, W. , 2007. Methods for determining cost-benefit ratios for pharmaceuticals in Germany. The European Journal of Health Economics, 8, 5–31.

Hong, C., Xie, Y., Yao, Y., Li, G., Yuan, X., & Shen, H. , 2015. A novel strategy for pharmaceutical cocrystal generation without knowledge of stoichiometric ratio: myricetin cocrystals and a ternary phase diagram. Pharmaceutical Research, 32, 47–60.

Huang, C.-Y., & Ku, M. S. , 2010. Prediction of drug particle size and content uniformity in low-dose solid dosage forms. International Journal of Pharmaceutics, 383, 70–80.

Issa, M. M., Shanab, A. A., & Shaat, N. T. , 2017. Double divisor mean centering of ratio spectra as a developed spectrophotometric method for the analysis of five-component mixture in drug analysis. Journal of Saudi Chemical Society, 21, S283–S292.

Jelić, A., Petrović, M., & Barceló, D. , 2009. Multi-residue method for trace level determination of pharmaceuticals in solid samples using pressurized liquid extraction followed by liquid chromatography/quadrupole-linear ion trap mass spectrometry. Talanta, 80, 363–371.

Khan, J., Alexander, A., Saraf, S., & Saraf, S. , 2013. Recent advances and future prospects of phyto-phospholipid complexation technique for improving pharmacokinetic profile of plant actives. Journal of Controlled Release, 168, 50–60.

Lasztity, A., Kelko-Levai, A., Varga, I., Zih-Perenyi, K., & Bertalan, E. , 2002. Development of atomic spectrometric methods for trace metal analysis of pharmaceuticals. Microchemical Journal, 73, 59–63.

Liu, J., Grohganz, H., Löbmann, K., Rades, T., & Hempel, N.-J. , 2021. Co-amorphous drug formulations in numbers: Recent advances in co-amorphous drug formulations with focus on co-formability, molar ratio, preparation methods, physical stability, in vitro and in vivo performance, and new formulation strategies. Pharmaceutics, 13, 389.

Loos, G., Van Schepdael, A., & Cabooter, D. , 2016. Quantitative mass spectrometry methods for pharmaceutical analysis. Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences, 374, 20150366.

Lotfy, H. M., Saleh, S. S., Hassan, N. Y., & Elgizawy, S. M. , 2012. *A comparative study of the novel ratio difference method versus conventional spectrophotometric techniques for the analysis of binary mixture with overlapped spectra*.

Palabiyik, I. M., Dinç, E., & Onur, F. , 2004. Simultaneous spectrophotometric determination of pseudoephedrine hydrochloride and ibuprofen in a pharmaceutical preparation using ratio spectra derivative spectrophotometry and multivariate calibration techniques. Journal of Pharmaceutical and Biomedical Analysis, 34, 473–483.

Patel, M. H., Mundada, V. P., & Sawant, K. K. , 2019. Novel drug delivery approach via self-microemulsifying drug delivery system for enhancing oral bioavailability of asenapine maleate: optimization, characterization, cell uptake, and in vivo pharmacokinetic studies. AAPS Pharmscitech, 20, 1–8.

Prajapati, P., & Agrawal, Y. K. , 2014. Analysis and impurity identification in pharmaceuticals. Reviews in Analytical Chemistry, 33, 123–133.

Runnqvist, H., Bak, S. A., Hansen, M., Styrishave, B., Halling-Sørensen, B., & Björklund, E. , 2010. Determination of pharmaceuticals in environmental and biological matrices using pressurised liquid extraction—are we developing sound extraction methods? Journal of Chromatography A, 1217, 2447–2470.

Sheikh, I. A., Charde, M. S., & Kasture, A. V. ,

2009. Estimation of Flupenthixol HCl in single dosage form by RP-HPLC method. International Journal of Pharmaceuticals Analysis, 1, 11.

Siddiqui, M. R., AlOthman, Z. A., & Rahman, N. , 2017. Analytical techniques in pharmaceutical analysis: A review. Arabian Journal of Chemistry, 10, S1409–S1421.

Singh, R. R., Angeles, L. F., Butryn, D. M., Metch, J. W., Garner, E., Vikesland, P. J., & Aga, D. S. , 2019. Towards a harmonized method for the global reconnaissance of multi-class antimicrobials and other pharmaceuticals in wastewater and receiving surface waters. Environment International, 124, 361–369.

Szepesi, G., Gazdag, M., & Mihályfi, K. , 1991. Selection of high-performance liquid chromatographic methods in pharmaceutical analysis: III. Method validation. Journal of Chromatography A, 464, 265–278.

Tallarida, R. J. , 1992. Statistical analysis of drug combinations for synergism. Pain, 49, 93–97.

Ternes, T. A. , 2001. Analytical methods for the determination of pharmaceuticals in aqueous environmental samples. TrAC Trends in Analytical Chemistry, 20, 419–434.

Vajna, B., Patyi, G., Nagy, Z., Bódis, A., Farkas, A., & Marosi, G. , 2011. Comparison of chemometric methods in the analysis of pharmaceuticals with hyperspectral Raman imaging. Journal of Raman Spectroscopy, 42, 1977–1986.

Watson, D. G. , 2012. *Pharmaceutical analysis E-book: a textbook for pharmacy students and pharmaceutical chemists*. Elsevier Health Sciences.